EDITAS MEDICINE, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
EDITAS MEDICINE, INC. (EDIT) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$89.33 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-02.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2023-08-02
- EDITAS MEDICINE, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-06-30 was -$40.29M.
- EDITAS MEDICINE, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-03-31 was -$49.04M.
- EDITAS MEDICINE, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-12-31 was -$60.74M.
- EDITAS MEDICINE, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-09-30 was -$55.73M.
- EDITAS MEDICINE, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$220.43M.
- EDITAS MEDICINE, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$192.50M.
- EDITAS MEDICINE, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$115.98M.
- EDITAS MEDICINE, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$133.75M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$40.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$89.33M 10-Q · filed 2023-08-02 | -$150.06M derived: sum of 3 quarters · filed 2023-08-02 | -$205.79M derived: sum of 4 quarters · filed 2023-08-02 |
| 2023-03-31 | -$49.04M 10-Q · filed 2023-05-05 | -$109.77M derived: sum of 2 quarters · filed 2023-05-05 | -$165.50M derived: sum of 3 quarters · filed 2023-05-05 | -$218.95M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-12-31 | -$60.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$116.46M derived: sum of 2 quarters · filed 2023-02-22 | -$169.92M derived: sum of 3 quarters · filed 2023-08-02 | -$220.43M 10-K · filed 2023-02-22 |
| 2022-09-30 | -$55.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$109.18M derived: sum of 2 quarters · filed 2023-08-02 | -$159.69M 10-Q · filed 2022-11-02 | -$201.13M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-06-30 | -$53.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$103.97M 10-Q · filed 2023-08-02 | -$145.40M derived: sum of 3 quarters · filed 2023-08-02 | -$184.49M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | -$50.52M 10-Q · filed 2023-05-05 | -$91.95M derived: sum of 2 quarters · filed 2023-05-05 | -$131.03M derived: sum of 3 quarters · filed 2023-05-05 | -$186.29M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | -$41.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$80.52M derived: sum of 2 quarters · filed 2023-02-22 | -$135.77M derived: sum of 3 quarters · filed 2023-02-22 | -$192.50M 10-K · filed 2023-02-22 |
| 2021-09-30 | -$39.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$94.34M derived: sum of 2 quarters · filed 2022-11-02 | -$151.07M 10-Q · filed 2022-11-02 | -$213.56M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | -$55.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$111.98M 10-Q · filed 2022-08-03 | -$174.48M derived: sum of 3 quarters · filed 2023-02-22 | -$166.66M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | -$56.73M 10-Q · filed 2022-05-04 | -$119.23M derived: sum of 2 quarters · filed 2023-02-22 | -$111.41M derived: sum of 3 quarters · filed 2023-02-22 | -$134.98M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | -$62.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$54.68M derived: sum of 2 quarters · filed 2023-02-22 | -$78.25M derived: sum of 3 quarters · filed 2023-02-22 | -$115.98M 10-K · filed 2023-02-22 |
| 2020-09-30 | $7.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$15.75M derived: sum of 2 quarters · filed 2021-11-09 | -$53.48M 10-Q · filed 2021-11-09 | -$91.25M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$23.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$61.30M 10-Q · filed 2021-08-05 | -$99.07M derived: sum of 3 quarters · filed 2022-02-24 | -$132.01M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$37.72M 10-Q · filed 2021-05-06 | -$75.49M derived: sum of 2 quarters · filed 2022-02-24 | -$108.44M derived: sum of 3 quarters · filed 2022-02-24 | -$142.22M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$37.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$70.71M derived: sum of 2 quarters · filed 2022-02-24 | -$104.50M derived: sum of 3 quarters · filed 2022-02-24 | -$133.75M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$32.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$66.73M derived: sum of 2 quarters · filed 2020-11-06 | -$95.98M 10-Q · filed 2020-11-06 | -$121.03M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$33.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$63.03M 10-Q · filed 2020-08-07 | -$88.09M derived: sum of 3 quarters · filed 2021-02-26 | -$103.33M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$29.25M 10-Q · filed 2020-05-08 | -$54.30M derived: sum of 2 quarters · filed 2021-02-26 | -$69.54M derived: sum of 3 quarters · filed 2021-02-26 | -$108.26M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$25.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$40.29M derived: sum of 2 quarters · filed 2021-02-26 | -$79.02M derived: sum of 3 quarters · filed 2021-02-26 | -$109.95M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$15.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$53.96M derived: sum of 2 quarters · filed 2019-11-12 | -$84.90M 10-Q · filed 2019-11-12 | -$121.09M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | -$38.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$69.66M 10-Q · filed 2019-08-07 | -$105.85M derived: sum of 3 quarters · filed 2020-02-26 | -$132.45M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | -$30.94M 10-Q · filed 2019-05-08 | -$67.13M derived: sum of 2 quarters · filed 2020-02-26 | -$93.73M derived: sum of 3 quarters · filed 2020-02-26 | -$120.17M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | -$36.19M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$62.79M derived: sum of 2 quarters · filed 2020-02-26 | -$89.23M derived: sum of 3 quarters · filed 2020-02-26 | -$120.32M 10-K · filed 2020-02-26 |
| 2017-09-30 | -$26.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$53.04M derived: sum of 2 quarters · filed 2018-11-08 | -$84.14M 10-Q · filed 2018-11-08 | -$123.51M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | -$26.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$57.54M 10-Q · filed 2018-08-07 | -$96.91M derived: sum of 3 quarters · filed 2019-03-01 | -$117.93M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | -$31.10M 10-Q · filed 2018-05-04 | -$70.47M derived: sum of 2 quarters · filed 2019-03-01 | -$91.49M derived: sum of 3 quarters · filed 2019-03-01 | |
| 2016-12-31 | -$39.38M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$60.40M derived: sum of 2 quarters · filed 2019-03-01 | -$97.18M 10-K · filed 2019-03-01 | |
| 2016-09-30 | -$21.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$57.81M 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | -$36.79M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | -$72.90M 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |